Sonoma Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sonoma Pharmaceuticals, Inc. (SNOA) on March 26, 2021. The filing discloses the entry into a material definitive agreement regarding the company's Microcyn technology platform.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a contractual agreement rather than periodic financial performance data.
Material Changes and Agreements
- Agreement Details: On March 26, 2021, the Company entered into an exclusive licensing and distribution agreement with EMC Pharma, LLC.
- Scope: EMC Pharma obtained the exclusive right to sell and distribute prescription dermatological and eye care products based on Sonoma's Microcyn technology in the United States.
- Terms: The agreement includes a five-year initial term, subject to mutual extension. EMC Pharma is obligated to purchase minimum product quantities and pay a quarterly royalty to retain exclusive rights.
Outlook, Risks, and Management Commentary
The filing contains forward-looking statements regarding the Company's intentions and expectations related to this agreement. Management notes that actual outcomes may differ materially due to risks and uncertainties discussed in the Company's Annual Report on Form 10-K. The Company does not undertake an obligation to update these statements except as required by law.
Key Facts for Investor Verification
- Verify the specific minimum purchase quantities and royalty rates required by EMC Pharma, as certain portions of the agreement were omitted for confidentiality.
- Confirm the impact of this exclusive distribution arrangement on future revenue recognition and gross margins for the Microcyn product line.
- Review the Company's Form 10-K for a comprehensive list of risk factors that could affect the execution of this agreement.